KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Debt: 2009-2024

Historic Non-Current Debt for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $16.0 billion.

  • Teva Pharmaceutical Industries' Non-Current Debt rose 2.23% to $16.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 billion, marking a year-over-year increase of 2.23%. This contributed to the annual value of $16.0 billion for FY2024, which is 11.89% down from last year.
  • Teva Pharmaceutical Industries' Non-Current Debt amounted to $16.0 billion in FY2024, which was down 11.89% from $18.2 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Non-Current Debt ranged from a high of $22.7 billion in FY2020 and a low of $16.0 billion during FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Non-Current Debt averaged around $17.8 billion, with its median value being $18.2 billion (2023).
  • Data for Teva Pharmaceutical Industries' Non-Current Debt shows a maximum YoY declined of 11.89% (in 2024) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non-Current Debt (Yearly) stood at $22.7 billion in 2020, then dropped by 4.90% to $21.6 billion in 2021, then declined by 11.63% to $19.1 billion in 2022, then declined by 4.93% to $18.2 billion in 2023, then declined by 11.89% to $16.0 billion in 2024.